Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suprachoroidal Triamcinolone for Resistant Uveitic Macular Edema
NCT07145008Phase 1Recruiting
- Sponsor
- College of Medicine, University of Baghdad
- Start
- Sep 2024
- Primary completion
- Jun 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of triamcinolone in macular edema and noninfectious uveitis (NIU), sponsored by College of Medicine, University of Baghdad. Primary endpoint: Visual acuity improvement at 3 months. Started Sep 2024; status: recruiting.
02
Drugs
triamcinolone
03
Conditions
macular edemanoninfectious uveitis (NIU)
Beyond the preview
Go deeper on NCT07145008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145008.